• Nektar Therapeutics recently launched preparations for its Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis, alongside presenting at the Jefferies Global Healthcare Conference 2026 and issuing inducement stock options to new hires under its 2025 Inducement Plan.
• The move to start a five-trial Phase 3 program for rezpegaldesleukin, in an atopic dermatitis market facing entrenched competitors and biosimilars, could be a pivotal test of Nektar’s immunology-focused business model.
• We’ll now examine how the upcoming Phase 3 ZENITH-AD program for rezpegaldesleukin may reshape Nektar’s investment narrative and risk profile.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Nektar Therapeutics Investment Narrative Recap

To own Nektar, you need to believe that REZPEG’s late stage trials can eventually support a first commercial product, while the company manages cash burn and dilution. The planned five study Phase 3 ZENITH AD program is the key near term catalyst, and trial execution and regulatory outcomes remain the biggest risks. The latest updates on timing and design of this program are important, but do not fundamentally change those core questions.

The most relevant recent announcement is Nektar’s plan to initiate the Phase 3 ZENITH AD program for REZPEG in July 2026, starting with two biologic naive atopic dermatitis studies and a first readout expected by mid 2028. This timetable gives investors a clearer sense of when pivotal data might emerge, but it also underlines the long period in which Nektar remains pre commercial and dependent on external funding to support ongoing R&D.

Yet behind the promise of Phase 3, investors should be aware that extended timelines and ongoing losses could still...

Nektar Therapeutics' narrative projects $54.9 million revenue and $10.7 million earnings by 2029. This implies fairly flat yearly revenue growth and a $168.8 million earnings increase from -$158.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $153.25 fair value, a 167% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$132.1 million in revenue and US$23.8 million in earnings by 2029, which is far more upbeat than consensus and may shift again as the Phase 3 ZENITH AD news is fully absorbed, so it is worth seeing how your own expectations compare with these very different views.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth just $153.25!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

No Opportunity In Nektar Therapeutics?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.